Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Publication Type:

Journal Article


The American journal of managed care, Volume 11, Issue 5, p.313-24 (2005)


Breast Neoplasms, Cost-Benefit Analysis, Drug Therapy, Humans, Lymph Nodes, Markov Chains, Receptors, Estrogen, Reverse Transcriptase Polymerase Chain Reaction


To appraise the economics of a recurrence score (RS), based on an assay that predicts distant recurrence-free survival in lymph-node-negative (LN-), estrogen-receptor-positive (ER+) patients with early-stage breast cancer receiving tamoxifen.